Krystal Biotech reported solid operational progress in Q1 2026, primarily driven by growth in sales of its gene therapy product VYJUVEK for dystrophic epidermolysis bullosa (DEB). The company leverages a differentiated HSV-1 vector platform enabling topical, redosable gene therapies with strong patent protection and regulatory approvals across the US, Europe, and Japan. Krystal’s vertical integration with two CGMP manufacturing sites supports scalability and supply control. While pipeline diversification into rare and some common diseases continues, reliance on VYJUVEK revenue and regulatory/pricing risks remain notable constraints. Monitoring clinical advancements and market penetration of existing and pipeline products will be key near-term indicators.